Leerink Highlights Biotechs Poised To Benefit From ASH Conference
Michael Schmidt and Jonathan Chang, analysts at Leerink, highlighted Juno, Karyopharm and Alnylam in their report ahead of the annual ASH Conference.
"ALNY will present important updates from ALN-CC5 (complement-mediated diseases) and ALN-AT3 (bleeding disorders) Phase I trials, respectively, including multi-dose cohorts, which should further validate early clinical results presented from either agent this summer."
"Six ASH presentations for JUNO will include updates from JCAR014 (anti-CD19, FHCRC) trials in NHL, chronic lymphocytic leukemia (CLL)... We'd expect updates at ASH to include more pts and data on durability in NHL, which could help position JUNO's product vs. competitors."
"Clinical data presentations on selinexor combinations include (1) a summary of Ph II dose finding trials showing that a flat dose of 60mg selinexor twice weekly provides the best risk-benefit profile."
Overall, the analysts believe that this presentation will contain meaningful data that could serve as catalysts for these companies going forward, particularly as it relates to Phase 1 and Phase 2 data. Positive data may validate early clinical results leading to positive investor sentiment.
Alnylam Pharmaceuticals shares recently traded at $105.37, down 1.87 percent on Monday.
Juno Therapeutics recently traded at $55.83, down 0.89 percent on Monday.
Karyopharm Therapeutics shares recently traded at $18.38, down 3.16 percent on Monday.
Image Credit: Public Domain
Latest Ratings for ALNY
|Feb 2017||Ladenburg Thalmann||Initiates Coverage On||Buy|
|Oct 2016||Morgan Stanley||Downgrades||Overweight||Equal-weight|
|Oct 2016||Stifel Nicolaus||Maintains||Hold|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.